ライフサイエンスコーパス: non-heart-beating donor

1 is particularly suited to retrieval from the non-heart beating donor.

2 l controversies remain concerning the use of non-heart-beating donors.

3 nal donor organs including those from viable non-heart-beating donors.

4 or=45 years), obese (weight >or=200 lb), and non-heart-beating donors and donors with an elevated amy

5 f several strategies, such as live donation, non-heart-beating donors, and expanded criteria donors.

6 Organs from non-heart-beating donors are attractive for use in cell

7 intact over prolonged periods after death in non-heart-beating donors, but extensive molecular pertur

8 reoxygenation will be highly significant for non-heart-beating donor cells.

9 feasibility of using livers from controlled, non-heart-beating donors (CNHBD) with good immediate gra

10 These data provide evidence that non-heart-beating donors could be a suitable source of h

11 Similarly, although hepatocytes from non-heart-beating donors engrafted and proliferated afte

12 uccessfully isolated viable hepatocytes from non-heart-beating donors, especially up to 4 hours after

13 ting long-waiting patients with kidneys from non-heart beating donors has reduced waiting times witho

14 Use of non-heart-beating donors, international organ sharing, a

15 Consent for cornea donation from non-heart-beating donors is often requested by means of

16 In non-heart-beating donors, liver tissue was morphological

17 ical impact of this technology in preserving non-heart-beating donor livers.

18 factors from the donors were suspected from non-heart-beating donors (n=1) and cardiac-arrest donors

19 Non-heart beating donors (NHBD) can provide an alternati

20 Donation of kidneys from non-heart beating donors (NHBD) is increasingly being us

21 tion solution (MPS) improves the function of non-heart-beating donor (NHBD) canine kidneys.

22 scribe a successful experience of controlled non-heart-beating donor (NHBD) liver transplantation.

23 Non-heart-beating donor (NHBD) livers are an untapped so

24 own to resuscitate and maintain viability of non-heart-beating donor (NHBD) livers that have undergon

25 ameliorates warm ischemic lung injury in the non-heart-beating donor (NHBD), thereby improving functi

26 Wide recruitment of non-heart-beating donors (NHBD) could significantly incr

27 Hepatic allografts from non-heart-beating donors (NHBD) have been cited as a mea

28 Non-heart-beating donors (NHBD) offer a potential source

29 Non-heart-beating donors (NHBD) offer a promising potent

30 particularly the case for organs taken from non-heart-beating donors (NHBD), but there is still a la

31 le, but little used, is that of kidneys from non-heart-beating donors (NHBD).

32 on coeficient (Kfc), in lungs retrieved from non-heart-beating donors (NHBDs) and reperfused with the

33 Non-heart-beating donors (NHBDs) are generally not deeme

34 Liver transplantation (LT) using grafts from non-heart-beating donors (NHBDs) has been shown to be a

35 Non-heart-beating donors (NHBDs) have the potential to r

36 Use of liver grafts from non-heart-beating donors (NHBDs) warrants consideration

37 timulated interest in the use of organs from non-heart-beating donors (NHBDs).

38 ted in the use of extended donors, including non-heart-beating donors (NHBDs).

39 s into molecular changes in hepatocytes from non-heart-beating donors offer opportunities for improvi

40 viability, which will advance the utility of non-heart-beating donor organs for cell therapy or other

41 We studied non-heart-beating donor rats for global gene expression

42 Ethical controversies in the use of non-heart-beating donors remain despite thorough review.

43 o our novel Bristol and Region Allocation by Non-heart beating Donor Score (BRANDS).

44 ssion profiling in hepatocytes isolated from non-heart-beating donors showed far greater perturbation

45 Uncontrolled non-heart-beating donor (UNHBD) transplantation offers a

46 be involved in withdrawal of life support in non-heart-beating donors, unless specialty trained in en

47 One kidney from 40 non-heart beating donors was allocated to the highest BR

48 ultiorgan transplantations, split grafts, or non-heart-beating donors were not included.

49 -ischemia time, prolonged donor hypotension, non-heart-beating donors) who received thymoglobulin ind